Section VII. Trends and perspectives

Publisher Summary This chapter discusses new therapeutic entities introduced worldwide in the markets in 1999. Among the new active entities marketed worldwide for human therapeutic use, the new biological entities (NBEs) that were biotechnology-based drugs (mainly recombinant proteins) represented a significant proportion. They represented innovative approaches to the treatment of several important human diseases. A total of 35 new therapeutic entities were introduced into their first markets in 1999, making it more productive than previous years 1995–1998. The launch of drugs considered as priority drugs, which represented significant therapeutic gains over the existing drugs for the patients and the medical community ranked particularly high. With 15 launches of new drugs, the US maintained their top rank in terms of new introductions, followed by Europe and Japan with 8 and 7 respectively. With 7 new launches, anti-infectives were one of the most active groups. An overview of different therapeutic entities is provided in the chapter, including abacavir sulfate (antiviral), alitretinoin (anticancer), amprenavir (antiviral), arglabin (anticancer), celecoxib (antiarthritic), cetrorelix, CHF-1301 (antiparkinsonian), colestimide (hypolipidaemic), colforsin daropate hydrochloride, denileukin diftitox (anticancer), and others.

[1]  D. Phillips,et al.  Clinical pharmacology of eptifibatide. , 1997, The American journal of cardiology.

[2]  M. Goldenberg,et al.  Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. , 1999, Clinical therapeutics.

[3]  J. Varghese,et al.  Development of neuraminidase inhibitors as anti‐influenza virus drugs , 1999 .

[4]  G. Burmester,et al.  Activation of monocytes by three OspA vaccine candidates: lipoprotein OspA is a potent stimulator of monokines. , 1997, FEMS immunology and medical microbiology.

[5]  K. Goa,et al.  Eptifibatide , 1999, Drugs.

[6]  C. Nightingale.  Moxifloxacin, a New Antibiotic Designed to Treat Community‐Acquired Respiratory Tract Infections: A Review of Microbiologic and Pharmacokinetic‐Pharmacodynamic Characteristics , 2000, Pharmacotherapy.

[7]  J. Blondeau.  A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'. , 1999, The Journal of antimicrobial chemotherapy.

[8]  L. Sorbera,et al.  ROSIGLITAZONE MALEATE : PROP INNM , 1998 .

[9]  Y. Toya,et al.  Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase. , 1998, Journal of molecular and cellular cardiology.

[10]  J. Blondeau,et al.  In Vitro and In Vivo Activity of Moxifloxacin against Community Respiratory Tract Pathogens , 1999 .

[11]  P. Galatsis.  Chapter 31. To Market, To Market - 1996 , 1997 .

[12]  H. Siragy.  Angiotensin II receptor blockers: review of the binding characteristics. , 1999, The American journal of cardiology.

[13]  M. West.  The cellular and molecular biology of skin aging. , 1994, Archives of dermatology.

[14]  L. Vacca,et al.  Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester , 1996, Journal of Neurology.

[15]  J. Miller,et al.  Inhibition of vinyl carbamate-induced hepatotoxicity, mutagenicity, and tumorigenicity by isopropyl-2-(1,3-dithietane-2-ylidene)-2-[N-(4-methylthiazol-2- yl)carbamoyl]acetate (YH439). , 1998, Carcinogenesis.

[16]  Eric J Topol,et al.  Platelet GPIIb-IIIa blockers , 1999, The Lancet.

[17]  H. Yamaguchi,et al.  Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. , 1997, Atherosclerosis.

[18]  H. Nakaya,et al.  Electropharmacology of Nifekalant, a New Class III Antiarrhythmic Drug , 1998 .

[19]  H. Himmel.  Naftopidil, A Novel Antihypertensive Drug , 1994 .

[20]  T. Morita,et al.  Lomerizine (KB-2796), a New Antimigraine Drug , 1995 .

[21]  M. Miyamoto,et al.  Synthesis and pharmacological studies of N-substituted 6-[(2-aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents. , 1992, Journal of Medicinal Chemistry.

[22]  A. MacGowan,et al.  Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. , 1999, Expert opinion on investigational drugs.

[23]  Greene,et al.  Rosiglitazone: a new therapy for Type 2 diabetes. , 1999, Expert opinion on investigational drugs.

[24]  H. Hayashi,et al.  Characterization of positive inotropic effect of colforsin dapropate hydrochloride, a water-soluble forskolin derivative, in isolated adult rat cardiomyocytes , 1999 .

[25]  U. Reichert,et al.  Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors , 1998, Cell Death and Differentiation.

[26]  R. Scarborough.  Development of eptifibatide. , 1999, American heart journal.

[27]  J. Cunningham.  What is the optimal regimen for vitamin D? , 1999, Kidney international. Supplement.

[28]  A. Schally,et al.  Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. , 1997, Advanced drug delivery reviews.

[29]  A. Dalhoff.  In vitro activities of quinolones. , 1999, Expert opinion on investigational drugs.

[30]  T. Batchelor,et al.  New treatment strategies for malignant gliomas. , 1999, The oncologist.

[31]  Michael J. Rybak,et al.  Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic , 1995, The Annals of pharmacotherapy.

[32]  Claude Carbón.  Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  D. Bouanchaud.  In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. , 1997, The Journal of antimicrobial chemotherapy.

[34]  J. Barciszewski,et al.  Kinetin — 45 years on , 1999 .

[35]  J. Tcheng.  Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. , 2000, American heart journal.

[36]  A. Krentz,et al.  Recent Developments and Emerging Therapies for Type 2 Diabetes Mellitus , 1999, Drugs in R&D.

[37]  P. Meredith.  Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. , 1999, The American journal of cardiology.

[38]  C. Silagy,et al.  Effectiveness and role of zanamivir in the treatment of influenza infection. , 1999, Annals of medicine.

[39]  Hun-Taek Kim,et al.  Synthesis and antitumor activity of (2R,3R)-2,3-dihydroxy- and -2,3-dialkoxy-1,4-diaminobutane platinum(II) complexes , 1996 .

[40]  David Back,et al.  Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection , 1999, Clinical pharmacokinetics.

[41]  J. Murphy,et al.  Targeting diphtheria toxin to growth factor receptors. , 1995, Seminars in cancer biology.

[42]  E S Newlands,et al.  Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. , 1997, Cancer treatment reviews.

[43]  S. Yamada,et al.  Alpha1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha1-antagonists , 1994 .

[44]  A. Schally.  Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆ , 1999, Peptides.

[45]  G. Mihm,et al.  6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. , 1993, Journal of medicinal chemistry.

[46]  U. Holzgrabe,et al.  [New 4-quinolone derivatives in review]. , 1999, Pharmazie in unserer Zeit.

[47]  D. Honeybourne,et al.  Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. , 1999, The European respiratory journal.

[48]  M. Goldberg,et al.  Clinical Pharmacology of Rapacuronium Bromide, a New Short‐Acting Neuromuscular Blocking Agent , 1999, Pharmacotherapy.

[49]  Xue-min Cheng.  Chapter 34. To Market, To Market - 1995 , 1996 .

[50]  M. Hayney,et al.  Lyme Disease Prevention and Vaccine Prophylaxis , 1999, The Annals of pharmacotherapy.

[51]  B. Sadler,et al.  141W94 : ANTI-HIV , 1996 .

[52]  L. Briceland,et al.  Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination. , 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[53]  B Testa,et al.  Esters of L‐Dopa: Structure‐hydrolysis Relationships and Ability to Induce Circling Behaviour in an Experimental Model of Hemiparkinsonism , 1995, The Journal of pharmacy and pharmacology.

[54]  K. Hashimoto,et al.  Cellular electrophysiological effects of MS‐551, a new class III antiarrhythmic agent , 1995 .

[55]  K. Goa,et al.  Zanamivir , 1999, Drugs.

[56]  A. Schally,et al.  Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. , 1995, Human reproduction.

[57]  L. Nagy,et al.  Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. , 1999, Current opinion in lipidology.

[58]  E. Boyce,et al.  Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis , 1999 .

[59]  K. Anderson,et al.  Effects of tumor necrosis factor-alpha treatment on mortality in murine cytomegalovirus-infected mice. , 1993, Antiviral research.

[60]  D. Handley.  The asthma-like pharmacology and toxicology of (S)-isomers of β agonists☆☆☆ , 1999 .

[61]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[62]  B. Gaudillière.  Chapter 31. To Market, To Market - 1998 , 1999 .

[63]  A. Schally.  LH-RH analogues: I. Their impact on reproductive medicine. , 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[64]  J. Barrett,et al.  A Review of the Preclinical Development of Zaleplon, a Novel Non-Benzodiazepine Hypnotic for the Treatment of Insomnia , 1997 .

[65]  H. Lamb,et al.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. , 2000, Drugs.

[66]  D. S. Kim,et al.  Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer. , 1999, American journal of clinical oncology.

[67]  L. Sorbera,et al.  ROFECOXIB : PROP INN , 1998 .

[68]  Y. Surh,et al.  Inhibition of covalent DNA binding and mutagenicity of benzo[a]pyrene by isopropyl-2-(1,3-dithietane-2-ylidene)-2-[N-(4-methylthiazol-2-yl) carbamoyl]acetate (YH439), a novel hepatoprotective agent. , 1996, Mutation research.

[69]  W. Mandeville,et al.  The Sequestration of Bile Acids, A Non-Absorbed Method for Cholesterol Reduction. A Review , 1997, Current Pharmaceutical Design.

[70]  R. Schoen,et al.  The Lyme Disease Vaccine: Conception, Development, and Implementation , 2000, Annals of Internal Medicine.

[71]  R. Jha.  Thiazolidinediones--the new insulin enhancers. , 1999, Clinical and experimental hypertension.

[72]  J. Lessem,et al.  Mechanisms and clinical effects of thiazolidinediones. , 1997, Expert opinion on investigational drugs.

[73]  R. Thurlow.  Treatment options for benign prostatic hyperplasia , 1998 .

[74]  I. Fraser,et al.  Investigation of a unique male and female sibship with Kallmann's syndrome and 46,XX gonadal dysgenesis with short stature. , 1999, Human reproduction.

[75]  M. Wood.  Chemotherapy for gram-positive nosocomial sepsis. , 1999, Journal of chemotherapy.

[76]  J. L. Napoli,et al.  Biochemical pathways of retinoid transport, metabolism, and signal transduction. , 1996, Clinical immunology and immunopathology.

[77]  C. Page,et al.  Contrasting properties of albuterol stereoisomers. , 1999, The Journal of allergy and clinical immunology.

[78]  J. Tcheng,et al.  Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa. , 1999, Expert opinion on investigational drugs.

[79]  P. Timmermans.  Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. , 1999, Hypertension research : official journal of the Japanese Society of Hypertension.

[80]  R. Wise.  A Review of the Clinical Pharmacology of Moxifloxacin, a New 8-Methoxyquinolone, and its Potential Relation to Therapeutic Efficacy , 1999 .

[81]  J. Kurtzberg,et al.  A phase I trial of recombinant human interleukin-1β(OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation , 1997, Bone Marrow Transplantation.

[82]  A. Schuna,et al.  New drugs for the treatment of rheumatoid arthritis. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[83]  R. Lotan,et al.  Aberrant Expression and Function of Retinoid Receptors in Cancer , 1999 .

[84]  G. Emons,et al.  Primary and salvage therapy with LH-RH analogues in ovarian cancer. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[85]  G. Sponer,et al.  Effects of naftopidil on some urodynamic parameters and arterial blood pressure in comparison with prazosin in conscious rats. , 1996, Pharmacological research.

[86]  C. Redfern.  Molecular Mechanisms of Retinoid Function , 1997 .

[87]  M. Bamberger,et al.  Chapter 10. Emerging Opportunities in the Treatment of Atherosclerosis , 1997 .

[88]  I. Miller,et al.  Zanamivir: a review of clinical safety. , 1999, Drug safety.

[89]  B. Kaplan-Machlis,et al.  The Cyclooxygenase-2 Inhibitors: Safety and Effectiveness , 1999, The Annals of pharmacotherapy.

[90]  B. Clark,et al.  Kinetin delays the onset of ageing characteristics in human fibroblasts. , 1994, Biochemical and biophysical research communications.

[91]  J. Costello.  Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol. , 1999, The Journal of allergy and clinical immunology.

[92]  H. Nelson.  Clinical experience with levalbuterol. , 1999, The Journal of allergy and clinical immunology.

[93]  J. Grippo,et al.  The discovery of 9-cis retinoic acid a hormone that binds the retinoid-X receptor , 1994, Trends in Endocrinology & Metabolism.

[94]  P. Galatsis.  Chapter 32 - To Market, To Market - 1997 , 1998 .

[95]  B. Conway,et al.  Pharmacology and clinical experience with amprenavir , 2000, Expert opinion on investigational drugs.

[96]  J. Delmez,et al.  Pathogenesis of secondary hyperparathyroidism. , 1999, Kidney international. Supplement.

[97]  M. Hosono.  [Cardiovascular effects of colforsin daropate hydrochloride, a novel drug for the treatment of acute heart failure]. , 1999, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[98]  Stephen H. D. Jackson.  INT CONGR SER , 2001 .

[99]  L. Kuritzky,et al.  Improving Management of Type 2 Diabetes Mellitus: 5. Thiazolidinediones , 2000, Hospital practice.

[100]  H. B. Fung,et al.  Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. , 1999, Clinical therapeutics.

[101]  W. Hening,et al.  Beyond Benzodiazepines: Alternative Pharmacologic Agents for the Treatment of Insomnia , 1998, The Annals of pharmacotherapy.

[102]  Xiaowu Chen,et al.  Neuraminidase Inhibitors as Anti-Influenza Virus Agents , 1999, Antiviral chemistry & chemotherapy.

[103]  G. Moyle.  Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection. , 2000, Current opinion in infectious diseases.

[104]  J. Ahn,et al.  Phase II clinical trial of SKI‐2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma , 1999, Cancer.

[105]  R. Mazess,et al.  Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. , 1997, Kidney international.

[106]  R. Lahita,et al.  Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs. , 2000, Geriatrics.

[107]  R. Hickey,et al.  Anthracycline antibiotic blockade of SV40 T antigen helicase action. , 1998, Biochemical pharmacology.